Similar companies
Related EMIS Industry Reports
The Company is a Korea-based company principally engaged in the marketing and distribution of biosimilar and biopharmaceutical medications developed and manufactured by Celltrion, Inc. The company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn's disease, psoriasis, psoriatic arthritis and ulcerative colitis. It also offers Truxima, a rituximab biosimilar used for the treatment of non-Hodgkin lymphomas, chronic lymphocytic leukemia and rheumatoid arthritis. The Company distributes its products within domestic market and to overseas markets. The Company was established onDecember 29, 1999. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on July 28, 2017.
Headquarters
4F, Celltrion Office Bldg, Academy-Ro 51Beon-Gil, Yeonsu-Gu
Incheon; Incheon;
Contact Details: Purchase the Celltrion Health Care Co.,Ltd. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service